AACR 2020: Final IMpower150 Analysis of Chemoimmunotherapy in Nonsquamous Lung Cancer
Posted: Wednesday, May 13, 2020
According to research presented as part of the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting (Abstract CT216), the chemoimmunotherapy regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel resulted in numerical—but statistically insignificant—improvement in overall survival compared with the same regimen without atezolizumab in patients with metastatic nonsquamous non–small cell lung cancer. However, the final analysis of the phase III IMpower150 study did identify a survival benefit associated with the quadruplet regimen in those with sensitizing EGFR mutations and liver metastases, according to Mark A. Socinski, MD, of the AdventHealth Cancer Institute in Orlando, and colleagues.
The study included 1,202 patients who were randomly assigned to receive either atezolizumab/carboplatin/paclitaxel (arm A), atezolizumab/bevacizumab/carboplatin/paclitaxel (arm B), or bevacizumab/carboplatin/paclitaxel (arm C). At a minimum follow-up of 32.4 months, the median overall survival for the intention-to-treat wild-type group in arm A (19.0 months) was superior to that in arm C (14.7 months). Both arms A and C experienced improvements in overall survival for subgroups for tumor cells 1/2/3 and tumor-infiltrating immune cells 1/2/3 wild type PD-L1, whereas neither arm experienced an improvement in overall survival in subgroups for tumor cells 0 or tumor-infiltrating immune cells 0 wild type.
Patients in both arms A and C who had EGFR/ALK-positive tumors or baseline liver metastases experienced similar overall survival, whereas patients in these subgroups had a prolonged overall survival in arm B versus arm C. The safety profile was consistent with the tolerability and toxicity findings reported at the second interim overall survival analysis.
Disclosure: For full disclosures of the study authors, visit abstractsonline.com.
